Oct 7, 2013
Recent Study: Aradigm Corporation (ARDM) - Medical Equipment - Deals and Alliances Profile
It carries out the development and commercialization of inhalation drugs for the prevention and treatment of severe respiratory diseases.
New Market Study Published: Human Genome Sciences, Inc. -...
It focuses on the discovery, development and commercialization of albumin fusion proteins, antibodies and proprietary technologies.
Disaster drill readies volunteers for anthrax attack
Once you're logged in, at the top of each article, video or slideshow you will see a list of your Facebook friends who recently visited Choose to share stories you'e read with your friends or turn sharing OFF to keep your reading experience anonymous .
The Motley Fool
Investing in Counteracting Biological and Chemical Agents
Chemical nerve agents have garnered much media coverage recently, but receiving less attention are the companies involved in the development of countermeasures to these and biological agents.
GSK signs a multi-year agreement with BARDA to supply the US government with anthrax treatment
GlaxoSmithKline plc today announced a new four year contract with the Biomedical Advanced Research and Development Authority , part of the US Department of Health and Human Services , for the provision of its inhalation anthrax treatment, raxibacumab.